Kimelman & Baird LLC Sells 350 Shares of Merck & Co., Inc. (NYSE:MRK)

Kimelman & Baird LLC reduced its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 0.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 162,550 shares of the company’s stock after selling 350 shares during the quarter. Merck & Co., Inc. makes up about 1.3% of Kimelman & Baird LLC’s portfolio, making the stock its 25th biggest holding. Kimelman & Baird LLC’s holdings in Merck & Co., Inc. were worth $16,170,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. State Street Corp boosted its stake in shares of Merck & Co., Inc. by 1.3% during the 3rd quarter. State Street Corp now owns 119,026,412 shares of the company’s stock worth $13,606,360,000 after acquiring an additional 1,536,474 shares during the period. Wellington Management Group LLP boosted its stake in shares of Merck & Co., Inc. by 4.6% during the 3rd quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock worth $8,608,914,000 after acquiring an additional 3,327,404 shares during the period. Geode Capital Management LLC boosted its stake in shares of Merck & Co., Inc. by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 59,155,004 shares of the company’s stock worth $6,696,060,000 after acquiring an additional 2,134,296 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Merck & Co., Inc. by 29.7% during the 4th quarter. Bank of New York Mellon Corp now owns 24,213,537 shares of the company’s stock worth $2,408,763,000 after acquiring an additional 5,550,824 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Merck & Co., Inc. by 7.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 20,125,171 shares of the company’s stock worth $2,002,052,000 after acquiring an additional 1,317,878 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. BMO Capital Markets dropped their price target on Merck & Co., Inc. from $105.00 to $96.00 and set a “market perform” rating for the company in a report on Wednesday, February 5th. UBS Group dropped their price objective on Merck & Co., Inc. from $125.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Hsbc Global Res raised Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 4th. TD Cowen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the company from $121.00 to $100.00 in a report on Monday, February 10th. Finally, Morgan Stanley dropped their price objective on Merck & Co., Inc. from $113.00 to $106.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Eleven analysts have rated the stock with a hold rating, nine have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $117.12.

View Our Latest Stock Report on MRK

Merck & Co., Inc. Trading Up 0.0 %

NYSE MRK opened at $94.72 on Monday. The business’s 50-day moving average price is $93.57 and its two-hundred day moving average price is $101.78. Merck & Co., Inc. has a 12 month low of $81.04 and a 12 month high of $134.63. The firm has a market capitalization of $239.27 billion, a PE ratio of 14.07, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The company has a current ratio of 1.36, a quick ratio of 1.15 and a debt-to-equity ratio of 0.79.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The company had revenue of $15.62 billion during the quarter, compared to the consensus estimate of $15.51 billion. During the same quarter last year, the firm posted $0.03 EPS. The company’s quarterly revenue was up 6.8% on a year-over-year basis. On average, analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be given a $0.81 dividend. The ex-dividend date of this dividend is Monday, March 17th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.42%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 48.14%.

Merck & Co., Inc. declared that its Board of Directors has initiated a share repurchase plan on Tuesday, January 28th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 4.1% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Merck & Co., Inc.

In other news, insider Cristal N. Downing sold 2,361 shares of the business’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $88.76, for a total value of $209,562.36. Following the transaction, the insider now directly owns 7,085 shares of the company’s stock, valued at $628,864.60. The trade was a 24.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Inge G. Thulin acquired 2,833 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was acquired at an average cost of $88.25 per share, for a total transaction of $250,012.25. Following the completion of the purchase, the director now directly owns 2,933 shares in the company, valued at $258,837.25. This trade represents a 2,833.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.